Benitec advancing gene therapy candidate BB-301; shares ahead 15% premarket – Seeking Alpha
|
Benitec advancing gene therapy candidate BB-301; shares ahead 15% premarket
Seeking Alpha Thinly traded nano cap Benitec Biopharma (NASDAQ:BNTC) is up 15% premarket on increased volume in response to its announcement that it is on track for an IND filing in Q4 2018 in the U.S. for gene therapy BB-301 for the treatment of oculopharyngeal … Benitec Biopharma provides update on OPMD orphan disease program |
